ArticleThe Journal of infectious diseases2017
Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining Serotypes.
Article in The Journal of infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Quantifying the benefits of improved operations for polio outbreak response: A model-based analysis.Vaccine · 2026Article
- Increasing Population Immunity Prior to Globally-Coordinated Cessation of Bivalent Oral Poliovirus Vaccine (bOPV).Pathogens (Basel, Switzerland) · 2024Article
- Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences.Risk analysis : an official publication of the Society for Risk Analysis · 2024Review
- The impact of disruptions caused by the COVID-19 pandemic on global polio eradication.Vaccine · 2023Article
- Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response.Vaccine · 2023Article
- Article
- Modeling scenarios for ending poliovirus transmission in Pakistan and Afghanistan.Risk analysis : an official publication of the Society for Risk Analysis · 2023Article
- Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation.Frontiers in public health · 2023Review
- Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation.Gates open research · 2023Article
- Reduced mucosal immunity to poliovirus after cessation of trivalent oral polio vaccine.Human vaccines & immunotherapeutics · 2021Article
- Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame.Risk analysis : an official publication of the Society for Risk Analysis · 2021Review
- Modeling and Managing Poliovirus Risks: We are Where we are….Risk analysis : an official publication of the Society for Risk Analysis · 2021Article
- Updated Characterization of Post-OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart.Risk analysis : an official publication of the Society for Risk Analysis · 2021Review
- Article
- Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication.Expert review of vaccines · 2020Review
- Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV).Expert review of vaccines · 2019Review
- Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine.Expert review of vaccines · 2018Review
- Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use.BMC infectious diseases · 2018Article
- Lessons From the Polio Endgame: Overcoming the Failure to Vaccinate and the Role of Subpopulations in Maintaining Transmission.The Journal of infectious diseases · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Comparing model expectations with the experience of oral poliovirus vaccine (OPV) containing serotype 2 (OPV2) cessation can inform risk management for the expected cessation of OPV containing serotypes 1 and 3 (OPV13). Methods: We compare the expected post-OPV2-cessation OPV2-related viruses from models with the evidence available approximately 6 months after OPV2 cessation. We also model the trade-offs of use vs nonuse of monovalent OPV (mOPV) for outbreak response considering all 3 serotypes. Results: Although too early to tell definitively, the observed die-out of OPV2-related viruses in populations that attained sufficiently intense trivalent OPV (tOPV) use prior to OPV2 cessation appears consistent with model expectations. As expected, populations that did not intensify tOPV use prior to OPV2 cessation show continued circulation of serotype 2 vaccine-derived polioviruses (VDPVs). Failure to aggressively use mOPV to respond to circulating VDPVs results in a high risk of uncontrolled outbreaks that would require restarting OPV. Conclusions: Ensuring a successful endgame requires more aggressive OPV cessation risk management than has occurred to date for OPV2 cessation. This includes maintaining high population immunity to transmission up until OPV13 cessation, meeting all prerequisites for OPV cessation, and ensuring sufficient vaccine supply to prevent and respond to outbreaks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.